Addex Therapeutics
ADXN
5 hedge funds and large institutions have $625K invested in Addex Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
1.57% more ownership
Funds ownership: 3.13% → 4.7% (+1.6%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
20% less capital invested
Capital invested by funds: $778K → $625K (-$153K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$138K |
| 2 |
Jane Street
New York
|
+$5.33K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$40 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$212 |
ADXN Hedge Fund Activity: Q3 2023 in Review
5 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q3 2023, worth a combined $625K — down 20% from $778K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ADXN positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $138K. The largest seller was Baader Bank Aktiengesellschaft, cutting an estimated $212.
- 5 institutional investors held Addex Therapeutics (ADXN) as of Q3 2023, up from 3 in Q2 2023.
- Funds reported $625K of Addex Therapeutics stock for Q3 2023, down 20% quarter-over-quarter.
- 2 funds opened new Addex Therapeutics positions in Q3 2023 and 0 closed out, a net change of +2 holders.
- The largest Addex Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $138K added.
- The largest Addex Therapeutics seller in Q3 2023 was Baader Bank Aktiengesellschaft, an estimated $212 sold.
Based on aggregated 13F filings for Q3 2023.